The size of the North America Gastroparesis Drugs market was around USD 1.90 billion in 2021. It is expected to grow at a CAGR of 4.5% to reach USD 2.37 billion by 2026. It captures 35% of the global market share.
The North American gastroparesis drugs market is majorly driven by the increasing incidence of the diabetic population across the region. Also, the rising number of surgical procedures further boosts the market growth. In North America, the senior population is considered one of the significant growth contributors to the gastroparesis drugs market. The growing geriatric population is more vulnerable to chronic diseases such as diabetes.
Other factors such as growing population and associated sedentary lifestyles, rapid urbanization, increasing consumption of alcohol and tobacco significantly influence market growth. In addition, the increasing research and development activities and clinical trials for Gastroparesis by the major companies in the region, primarily due to the high prevalence rate of diabetes type 1 and diabetes type 2, are expected to provide lucrative growth opportunities to market growth. Emerging countries such as U.S. and Canada have witnessed advanced healthcare infrastructure, high healthcare spending, and government initiatives to adopt new user-friendly drugs is more likely to accelerate the regional market growth.
Increasing investments and funding by the government and manufacturers in research and development activities to develop advanced, new approaches to the existing drug therapy are expected to uplift the market growth. Furthermore, the market participants' innovative market strategies in the region's emerging countries are expected to provide lucrative growth opportunities for market expansion.
However, the side effects of gastroparesis drugs and complications in gastroparesis diagnosis are limiting the market growth. In addition, a time-consuming regulatory process for the approval of drugs is further hinders market growth.
This research report on the North American gastroparesis drugs market has been segmented and sub-segmented into the following categories.
By Drug Class:
By Disease Class:
By End User:
Geographically, the North American market dominated the global gastroparesis drugs market, and it is anticipated to continue its dominance throughout the forecast period. The regional market growth is attributed to the high prevalence rate of Gastroparesis, growing awareness, and high healthcare expenditure. In addition, the presence of well-established healthcare infrastructure, key market players, and favorable government policies are contributing to the market growth. The highly economic countries such as the United States and Canada significantly contribute to the North American regional market expansion.
The United States accounted for the largest share of the market. It is expected to witness a predominant share owing to the Y-0-Y rising older population, increasing diabetic population, and the introduction of novel drugs.
However, according to a review of Diabetic Gastroparesis for the Community Pharmacist, the US has diabetes and has faced complications associated with the disease. Diabetes is the most common systemic disease that causes Gastroparesis. Moreover, extensive research and development activities in pharmaceutical and biotechnology companies in the country are boosting market growth.
On the other hand, the Canadian gastroparesis market is projected to witness a considerable share during the forecast period.
KEY MARKET PLAYERS:
Companies playing a leading role in the North American gastroparesis drugs market profiled in this report are Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.2 Prokinetic Agents
5.1.3 Antiemetic Agents
5.1.4 Botulinum Toxin Injections
5.1.5 Y-o-Y Growth Analysis, By Drug Class
5.1.6 Market Attractiveness Analysis, By Drug Class
5.1.7 Market Share Analysis, By Drug Class
5.2 Disease Type
5.2.2 Diabetic Gastroparesis
5.2.3 Idiopathic Gastroparesis
5.2.4 Post-surgical Gastroparesis
5.2.6 Y-o-Y Growth Analysis, By Disease Type
5.2.7 Market Attractiveness Analysis, By Disease Type
5.2.8 Market Share Analysis, By Disease Type
5.3 End User
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Drug Class
184.108.40.206 By Disease Type
220.127.116.11 By End User
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Drug Class
126.96.36.199 By Disease Type
188.8.131.52 By End User
6.1.5 Market Share Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Drug Class
18.104.22.168 By Disease Type
22.214.171.124 By End User
6.2 United States
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Allergan, Plc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)
8.3 AstraZeneca Plc.
8.4 Cadila Pharmaceuticals Ltd.
8.5 ETX Pharma, Inc
8.6 Evoke Pharma
8.7 GlaxoSmithKline Plc.
8.8 Neurogastrx, Inc.
8.9 Valeant Pharmaceuticals International, Inc.
8.10 Theravance Biopharma
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures